Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

NCT01794299 is registered in ClinicalTrials.gov with Kiadis Pharma as lead sponsor.

NCT NCT01794299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01794299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Lead sponsor
Kiadis Pharma
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2013
Completion date
September 30, 2017
Enrollment
31 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome